MedTrace Logo

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

NCT05184179 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5450

Last updated 2024-07-01

No results posted yet for this study

Summary

Throughout this study, the efficacy and safety information of Olomax tablets will be collected from 24 weeks to 48 weeks(+8 weeks) The Data collection point is baseline, at more than 24 weeks, at more than 48 weeks(+8 weeks).

Conditions

Interventions

DRUG

Olmesartan Medoxomil

Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-08-16
Completion
2022-08-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184179 on ClinicalTrials.gov